A model-based cost-effectiveness analysis of fracture liaison services in China

Nannan Li*, Lei Si, Annelies Boonen, Joop P van den Bergh, Mickaël Hiligsmann

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Web of Science)
9 Downloads (Pure)

Abstract

This study is a model-based cost-effectiveness analysis of fracture liaison services (FLS) in China, suggesting that FLS could potentially lead to lifetime cost-saving in patients who have experienced a fracture. However, Chinese-specific real-world data is needed to confirm the results of our study.

PURPOSE: The study aimed to assess the potential cost-effectiveness of fracture liaison services (FLS) from the Chinese healthcare perspective with a lifetime horizon.

METHODS: A previously validated Markov microsimulation model was adapted to estimate the cost-effectiveness of FLS compared to no-FLS. The evaluation was conducted in patients aged 65 years with a recent fracture. Treatment pathways were differentiated by gender, FLS attendance, osteoporosis diagnosis, treatment initiation, and adherence. Given the uncertainty in FLS cost, the cost in the base-case analysis was assumed at US$200. Analyses were also performed to determine the maximum cost for making the FLS cost-saving and cost-effective at the Chinese willingness-to-pay (WTP) threshold. One-way sensitivity analyses were conducted.

RESULTS: When compared with no-FLS, the FLS was dominant (lower costs, higher quality-adjusted life years) in our target population at the FLS cost of US$200 per patient. For every 100 patients who were admitted to the FLS, approximately four hip fractures, nine clinical vertebral fractures, and three wrist fractures would be avoided over their lifetimes. Our findings were robust to numerous one-way sensitivity analyses; however, the FLS was not cost-effective in patients aged 80 years and older.

CONCLUSION: FLS could potentially lead to lifetime cost-saving in patients who have experienced a fracture. Our study informs the potential cost-effectiveness of FLS and the knowledge gap in China; more future research incorporating Chinese-specific real-world data are needed to confirm the results of our study and to better evaluate the cost-effectiveness of FLS in China.

Original languageEnglish
Article number132
Number of pages13
JournalArchives of Osteoporosis
Volume17
Issue number1
DOIs
Publication statusPublished - 5 Oct 2022

Keywords

  • Bone Density Conservation Agents/therapeutic use
  • China/epidemiology
  • Cost-Benefit Analysis
  • Humans
  • Osteoporosis/drug therapy
  • Osteoporotic Fractures/drug therapy
  • Quality-Adjusted Life Years
  • Secondary Prevention

Cite this